Can-Fite BioPharma Ltd.
CANFHealthcare|Biotechnology|IL
$1.62
+0.02 (+1.25%)
Tangible Book / Share
$2.62
Cash / Share
$3.80
Financials
Financial Snapshot
Market Cap
$2.1M
Enterprise Value
$701.4K
Revenue (TTM)
$405.0K
Net Income (TTM)
-$9.6M
Cash & Investments
$7.0M
Net Cash
$7.0M
Free Cash Flow (TTM)
-$9.5M
Operating CF (TTM)
-$9.5M
Debt/Equity
0.01
Cash Runway & Burn Rate
Cash on Hand
$7.0M
Quarterly Burn
$2.4M
Monthly Burn
$792.6K
Est. Runway
~3.0 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $8.1M | $3.5M | $3.9M | $2.8M | $8.3M | $19.1M | $8.0M | $8.9M | $7.9M | $8.5M | $7.0M | |
| Operating Cash Flow | -$8.9M | -$9.5M | -$4.2M | -$10.8M | -$12.1M | -$9.9M | -$10.8M | -$8.4M | -$7.6M | -$9.0M | -$9.5M | |
| Free Cash Flow | -$8.9M | -$9.5M | -$4.2M | -$10.8M | -$12.1M | -$9.9M | -$10.8M | -$8.4M | -$7.6M | -$9.0M | -$9.5M | |
| Capital Expenditure | -$10.4K | -$6.9K | -$33.0K | -$3.0K | -$26.0K | -$11.0K | -$9.0K | -$2.0K | -$5.0K | -$2.0K | -$2.0K | |
| Financing Cash Flow | $0.00 | $4.9M | $4.4M | $10.2M | $17.7M | $20.5M | $0.00 | $9.1M | $6.7M | $9.7M | $10.0M |
R&D Spending
R&D (TTM)
$7.1M
R&D Intensity
1756.8%
R&D Growth vs Prior
+5.5%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $169.5K | $844.7K | $3.8M | $2.0M | $763.0K | $853.0K | $810.0K | $743.0K | $674.0K | $408.2K | $405.0K | |
| R&D Expense | $6.1M | $5.3M | $6.1M | $11.0M | $12.0M | $9.8M | $7.8M | $6.0M | $5.8M | $6.7M | $7.1M | |
| R&D % of Revenue | 3585.9% | 624.0% | 159.0% | 540.2% | 1566.3% | 1154.7% | 958.4% | 805.2% | 854.2% | 1652.6% | 1756.8% | |
| SG&A | $2.7M | $2.9M | $3.2M | $3.1M | $3.0M | $3.8M | $3.1M | $3.0M | $3.0M | $3.7M | $3.0M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $169.5K | $844.7K | $3.8M | $2.0M | $763.0K | $853.0K | $810.0K | $743.0K | $674.0K | $408.2K | $405.0K | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $24.2K | $0.00 | |
| Gross Profit | $169.5K | $844.7K | $3.8M | $2.0M | $763.0K | $853.0K | $810.0K | $743.0K | $674.0K | $384.0K | $405.0K | |
| R&D | $6.1M | $5.3M | $6.1M | $11.0M | $12.0M | $9.8M | $7.8M | $6.0M | $5.8M | $6.7M | $7.1M | |
| SG&A | $2.7M | $2.9M | $3.2M | $3.1M | $3.0M | $3.8M | $3.1M | $3.0M | $3.0M | $3.7M | $3.0M | |
| Operating Income | -$8.6M | -$7.4M | -$5.4M | -$12.0M | -$14.1M | -$12.8M | -$10.1M | -$8.2M | -$8.1M | -$10.0M | -$9.7M | |
| Interest Expense | $27.3K | $1.1M | $1.2M | $427.0K | $363.0K | $18.0K | $77.0K | $14.0K | $14.0K | $14.1K | $0.00 | |
| Pretax Income | -$7.0M | -$5.0M | -$6.6M | -$12.6M | -$14.4M | -$12.6M | -$10.2M | -$7.6M | -$7.9M | -$9.9M | -$9.6M | |
| Net Income | -$6.9M | -$5.0M | -$6.6M | -$12.6M | -$14.4M | -$12.6M | -$10.2M | -$7.6M | -$7.9M | -$9.9M | -$9.6M | |
| EPS (Diluted) | -0.60 | -0.38 | -0.34 | -0.30 | -0.08 | -0.06 | -0.03 | -0.01 | -0.01 | -0.08 | -1.26 | |
| EBITDA | -$8.7M | -$7.2M | -$6.1M | -$12.0M | -$14.1M | -$12.8M | -$10.1M | -$8.2M | -$8.1M | -$10.0M | -$9.7M | |
| Shares Out. (M) | 13.85 | 16.26 | 19.45 | 42.95 | 179.21 | 276.54 | 407.87 | 639.17 | 1087.96 | 123.59 | 3.71 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.1M | $3.5M | $3.6M | $2.7M | $8.3M | $4.4M | $3.0M | $4.3M | $4.8M | $5.5M | $3.0M | |
| Short-Term Investments | $0.00 | $0.00 | $273.0K | $64.0K | $75.0K | $14.7M | $5.0M | $4.6M | $3.1M | $3.0M | $4.1M | |
| Total Current Assets | $10.1M | $6.9M | $7.9M | $7.1M | $9.4M | $20.1M | $9.2M | $9.9M | $9.0M | $9.4M | $8.0M | |
| Total Assets | $10.2M | $7.8M | $8.0M | $8.2M | $9.5M | $20.3M | $9.3M | $10.0M | $9.1M | $9.5M | $8.1M | |
| Total Current Liabilities | $2.5M | $1.8M | $3.1M | $3.3M | $1.3M | $2.7M | $2.5M | $2.0M | $2.1M | $2.7M | $2.2M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $6.3M | $4.8M | $4.9M | $5.7M | $3.4M | $5.9M | $4.8M | $3.7M | $3.7M | $3.9M | $3.2M | |
| Stockholders' Equity | $3.9M | $3.1M | $3.0M | $2.4M | $6.1M | $14.4M | $4.5M | $6.2M | $5.4M | $5.6M | $4.9M | |
| Retained Earnings | -$91.0M | -$105.7M | -$100.6M | -$110.3M | -$125.5M | -$140.7M | -$150.8M | -$158.5M | -$166.4M | -$176.2M | -$180.8M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$8.9M | -$9.5M | -$4.2M | -$10.8M | -$12.1M | -$9.9M | -$10.8M | -$8.4M | -$7.6M | -$9.0M | -$9.5M | |
| Capital Expenditure | -$10.4K | -$6.9K | -$33.0K | -$3.0K | -$26.0K | -$11.0K | -$9.0K | -$2.0K | -$5.0K | -$2.0K | -$2.0K | |
| Free Cash Flow | -$8.9M | -$9.5M | -$4.2M | -$10.8M | -$12.1M | -$9.9M | -$10.8M | -$8.4M | -$7.6M | -$9.0M | -$9.5M | |
| Investing Cash Flow | -$10.4K | -$29.6K | -$33.0K | -$253.0K | -$26.0K | -$14.5M | $9.5M | $498.0K | $1.5M | -$2.0K | -$4.0M | |
| Financing Cash Flow | $0.00 | $4.9M | $4.4M | $10.2M | $17.7M | $20.5M | $0.00 | $9.1M | $6.7M | $9.7M | $10.0M | |
| Issuance of Stock | $0.00 | $4.5M | $4.4M | $10.2M | $17.7M | $20.5M | $0.00 | $9.1M | $6.7M | $9.7M | $0.00 | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | -$34.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $309.0K | $195.1K | $535.0K | $385.0K | $355.0K | $466.0K | $263.0K | $261.0K | $362.0K | $340.0K | $181.0K | |
| Net Change in Cash | -$9.1M | -$5.5M | $110.0K | -$918.0K | $5.6M | -$3.9M | -$1.4M | $1.3M | $547.0K | $702.9K | $0.00 |
Dilution Tracker
Shares Outstanding
1M
5-Year Share Growth
-31.0%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 13.85 | 16.26 | 19.45 | 42.95 | 179.21 | 276.54 | 407.87 | 639.17 | 1087.96 | 123.59 | 3.71 | |
| Change vs Prior % | — | 17.5% | 19.6% | 120.8% | 317.2% | 54.3% | 47.5% | 56.7% | 70.2% | -88.6% | -97.0% | |
| Stock Issuance | $0.00 | $4.5M | $4.4M | $10.2M | $17.7M | $20.5M | $0.00 | $9.1M | $6.7M | $9.7M | $0.00 | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $309.0K | $195.1K | $535.0K | $385.0K | $355.0K | $466.0K | $263.0K | $261.0K | $362.0K | $340.0K | $181.0K |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 94.1% | 100.0% | |
| Operating Margin % | -5093.7% | -873.1% | -141.7% | -590.9% | -1853.1% | -1505.5% | -1246.4% | -1103.0% | -1206.2% | -2456.8% | -2403.0% | |
| Net Margin % | -4069.3% | -588.2% | -172.0% | -621.3% | -1892.9% | -1476.6% | -1255.9% | -1027.5% | -1169.1% | -2426.7% | -2358.8% | |
| EBITDA Margin % | -5119.2% | -848.3% | -160.4% | -590.2% | -1851.5% | -1503.9% | -1244.7% | -1100.9% | -1205.2% | -2450.9% | -2402.5% | |
| FCF Margin % | -5273.0% | -1128.2% | -109.6% | -533.3% | -1584.4% | -1157.0% | -1334.6% | -1136.2% | -1133.8% | -2210.1% | -2348.9% | |
| ROE % | -178.4% | -162.7% | -217.9% | -517.0% | -237.8% | -87.6% | -227.5% | -122.3% | -145.0% | -177.1% | -182.9% | |
| ROA % | -67.8% | -63.4% | -82.6% | -154.5% | -151.7% | -62.2% | -109.6% | -76.4% | -86.4% | -104.1% | -118.6% | |
| ROIC % | -104.9% | -122.2% | -112.0% | -243.1% | -170.4% | -72.9% | -147.8% | -102.5% | -114.2% | -146.6% | -165.6% | |
| R&D / Revenue % | 3585.9% | 624.0% | 159.0% | 540.2% | 1566.3% | 1154.7% | 958.4% | 805.2% | 854.2% | 1652.6% | 1756.8% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.9% | 398.4% | 352.2% | -46.8% | -62.5% | 11.8% | -5.0% | -8.3% | -9.3% | -39.4% | |
| Gross Profit | 2.9% | 398.4% | 352.2% | -46.8% | -62.5% | 11.8% | -5.0% | -8.3% | -9.3% | -43.0% | |
| Operating Income | -34.6% | 14.6% | 26.6% | -121.8% | -17.8% | 9.2% | 21.4% | 18.8% | 0.8% | -23.4% | |
| Net Income | -43.8% | 28.0% | -32.2% | -92.1% | -14.4% | 12.8% | 19.2% | 25.0% | -3.2% | -25.7% | |
| EPS (Diluted) | -11.1% | 36.7% | 10.5% | 11.8% | 71.8% | 35.0% | 54.5% | 52.0% | 40.0% | -1013.9% | |
| Operating Cash Flow | -91.9% | -6.7% | 56.4% | -160.7% | -11.3% | 18.3% | -9.6% | 21.9% | 9.5% | -18.1% | |
| Free Cash Flow | -90.3% | -6.6% | 56.1% | -158.8% | -11.6% | 18.4% | -9.5% | 21.9% | 9.5% | -18.1% | |
| R&D Expense | 57.6% | -13.3% | 15.2% | 80.7% | 8.9% | -17.6% | -21.2% | -22.9% | -3.8% | 17.2% | |
| SG&A Expense | -0.1% | 9.4% | 7.1% | -3.0% | -3.7% | 30.3% | -18.3% | -6.0% | 3.1% | 20.3% | |
| Total Assets | -42.2% | -23.0% | 1.5% | 2.8% | 16.5% | 112.7% | -54.2% | 7.6% | -8.7% | 4.3% | |
| Book Value / Share | -69.3% | -32.9% | -17.5% | -63.3% | -37.4% | 76.2% | -82.5% | -10.9% | -48.8% | 805.6% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | -10.7% | 85.1% | -50.0% | -35.5% | 160.0% | -31.7% | |
| Diluted Shares | 20.6% | 17.5% | 19.6% | 120.8% | 317.2% | 54.3% | 47.5% | 56.7% | 70.2% | -88.6% |
Valuation
P/E (TTM)At Loss
P/S8.98
10Y Low / Med / High1211.03 / 61432.75 / 583261.50
P/B0.65
10Y Low / Med / High88.41 / 11127.13 / 25575.75
EV/EBITDAAt Loss
EV/Revenue1.73
10Y Low / Med / High1197.66 / 61429.15 / 583213.65
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$2.62
Net Current Assets / Share
$3.67
Graham Net-Net
$2.07
Cash / Share
$3.80
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -11900.00 | -11684.21 | -11117.65 | -2200.00 | -4208.04 | -4300.00 | -4880.00 | -3666.67 | -4527.78 | -49.88 | -0.24 | |
| P/S Ratio | 583261.50 | 85476.35 | 19247.43 | 13951.90 | 79670.05 | 69396.40 | 61432.75 | 37851.07 | 52622.56 | 1211.03 | 8.98 | |
| P/B Ratio | 25575.75 | 23644.10 | 24386.46 | 11609.44 | 10007.94 | 4115.92 | 11127.13 | 4504.78 | 6524.58 | 88.41 | 0.65 | |
| EV/EBITDA | -11392.73 | -10075.68 | -12001.56 | -2363.68 | -4302.40 | -4614.19 | -4935.29 | -3437.54 | -4365.74 | -48.87 | -0.07 | |
| EV/Revenue | 583213.65 | 85472.21 | 19246.48 | 13950.61 | 79659.30 | 69391.40 | 61429.15 | 37845.37 | 52615.55 | 1197.66 | 1.73 |
Analyst Estimates & Quality
Altman Z-Score
-34.10
Distress
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $404.0K | $404.0K | $15.3M |
| Net Income | -$252.1M | -$112.5M | -$79.1M |
| EPS | $-2.04 | $-0.91 | $-0.64 |
| # Analysts (EPS) | 1 | 1 | 1 |